TRESIBA
(insulin degludec)PreclinicalBiologic
Novo NordiskTRESIBA is one of 46 biologic programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
45
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
GZR4
GGan and Lee Pharmaceuticals, USA
Phase 3
HM11260C
Hanmi Pharmaceutical Company LimitedPhase 3
TG103
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Dostinex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Sep 25, 2015
TRESIBA
BLA BLA203314
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for insulin degludec. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company